Symptom management is the most common category of medical treatment in the ambulatory setting. The majority of visits (69%) are for diagnosis and/or evaluation. Physical, mental, and behavioral health issues are also common. There are several common treatments for medical conditions, including the management of diarrhea.
The syndrome model is a useful method for identifying syndromes in complex diseases. The definition of syndrome as something related to disease but not the disease itself can lead to different definitions of syndrome by different researchers. The definition and the definition of syndromes by different researchers can lead to different syndromes and to different definitions of syndromes within each syndrome. It is therefore important to consider some aspects of the definition of syndromes when designing syndrome databases such as the NCI-funded NIH-funded Syndromic Collections of Excellence (SYCE).
There are a number of causes responsible for syndrome. There is discussion as to the appropriate treatment for each syndrome and its treatment is highly dependent on each individual case.
The authors suggest that syndromic disorders may result from a combination of genetic and lifestyle factors, a complex genetic mix, the influence of environmental factors and individualized treatment.
Data from a recent study indicated that syndrome is a relatively very common condition in United States, with an incidence of 2.3% per year. Although the etiology of syndrome remains unknown, the number of individuals affected with it will be expanding.
The term syndrome, or group of symptoms, cannot be cured. Nevertheless, a syndromic presentation may be resolved in one patient or family. In the absence of specific information, the term syndrome may be helpful in communicating the complexity and breadth of the problems to multiple providers and the patient.
Syndromes are the presentation of the same disease but have some notable differences. They can be identified according to the presence/absence of symptoms. The different presentation of the syndrome can have significant effects on how well a patient can be diagnosed and treated. This article presents recent advances in syndrome research.
The seriousness of the disease as determined by the number of patients affected and the number of deaths should be taken into account. Results from a recent paper also indicates that syndrome is a disease in the category of severe diseases. This requires more attention and, perhaps, more specific treatments.
ELAPRASE is effective and well tolerated in severe adult cases of lHAS. Results of this study suggest that ELAPRASE is less efficacious in neonatal cases of lHAS. ELAPRASE significantly reduces ELAPROTEN, indicating a reduction in elafin activity. Reduction of elafin in the blood coincides with a reduction in elafin activity in cultured monocytes and platelets. Further work will focus on the clinical significance of these findings and, if translocated to clinical use, whether ELAPRASE is effective at a lower dose than the normal dose.
Elaprase is an oral, sustained-release formulation of rhAGP with an increased half-life that is approved for the treatment of hemophilia A. It is manufactured by CSL Behring in the Czech Republic. A prescription medication, it is marketed and distributed by Schering-Plough, in collaboration with CSL Behring, LLC. CSL Behring offers elaprase as a self-administered product to people who require treatment at least once weekly. Because elaprase has an increased half-life relative to rhAGP, elaprase has been studied as a therapeutic option for people with hemophilia A.
The average age of onset is 64.8 years of age, with a minimum age of 58 years. This mean age is somewhat variable by medical center; it tends to be higher when more patients were diagnosed in a single year. The syndrome may appear later in life and have a different etiology and course. The average interval from disease onset to diagnosis is 10.3 months.
Two thirds of cases in our cohort were familial, supporting the notion that familial factors play a contributory role in the pathogenesis of LEN. Because of recent evidence of the role of microRNAs in several autoimmune diseases as well as the increasing interest in miRNA in cancer genetics, we speculate that a miRNA-induced dysregulation of the human leukocyte antigens might in part or wholly explain the familial pattern of the disease in our cases.